Valneva SE
Valneva SE (VALN) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · VALN · as of Jun 8, 2026
Key Statistics
Explore Valneva SE Data
valn stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 2 · Buy rate: 100.0%
The VALN analyst consensus is Buy, based on ratings from 2 Wall Street analysts over the past 3 months. The average 12-month price target is $11.00, representing +106.19% upside from the current price of $5.33.
Competitors & Peers
valn competitorsVALN
ARVN
ATXS
AVBP
DAWN
DNAStock Performance
Full HistoryAbout Valneva SE
Valneva SE operates as a specialized biopharmaceutical company, concentrating its efforts on developing and bringing to market preventative vaccines for infectious diseases where current medical optio…
what is valneva se · valn stock overview · valneva se company profile · who is valneva se ceo · valn NASDAQ · valneva se headquarters · valneva se business segments
About Stock Overview & Key Data
Valneva SE (VALN) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since May 5, 2021. As of the latest trading session, VALN stock price is $5.33, with a market capitalization of $475.1M. The stock has returned -10.69% over the past 12 months and -38.44% year-to-date.
According to 2 Wall Street analysts, the consensus rating for Valneva SE stock is Buy, with an average 12-month price target of $11.00. In fiscal year 2025, Valneva SE reported revenue of $174.7M and net income of -$115.2M. For detailed data — including Valneva SE revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Valneva SE (VALN) stock price is $5.33. The stock is traded on NASDAQ under the ticker symbol VALN. The 52-week range is $5.06 – $12.25.